Overview

Fulvestrant in Metastatic Breast Cancer

Status:
Unknown status

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This is a prospective study of the role of fulvestrant in combination with ovarian function suppression as first-line therapy in premenopausal patients with metastatic hormone receptor-positive breast cancer.

Phase:

Phase 4

Details

Lead Sponsor:

Assiut University

Treatments:

Estradiol
Fulvestrant
Goserelin